No Pain, Lots To Gain: Vertex Looks For Non-Opioid Drug Breakthrough
Phase III Readout Expected By Early 2024
Executive Summary
Vertex is closing in on annual revenues of $10bn from its cystic fibrosis drugs, but non-opioid pain therapy candidate VX-548 could open up a whole new blockbuster revenue stream if Phase III studies go to plan.
You may also be interested in...
Latigo Raises $135m To Channel Vertex
The start-up is aiming to develop a NaV1.8 inhibitor for pain, but previous efforts here have met with more failure than success.
Vertex’s Non-Opioid Pain Candidate Hits Marks In Diabetic Peripheral Neuropathy
VX-548, which is set to read out Phase III data in acute pain in early 2024, demonstrated initial efficacy in chronic pain, but analysts say the drug will have to compete mainly on safety and tolerability.
Vertex’s R&D Leader On Sickle Cell Challenges And ‘Out-Innovating’ Itself
A few years ago, investors were calling on Vertex to buy in late-stage innovation, but its focus on audacious drug development goals looks set to pay off with a groundbreaking CRISPR-based sickle cell disease cell therapy approaching the market. Its R&D head David Altshuler talked to Scrip about its approach.